arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nexalin Technology, Inc.

NXL
$1.53 0.00 (0.00%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
23 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nexalin Technology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $32.3M
Dividend Yield —
Revenue Growth -82.8% ↘
Op. Margin None
ROIC -116.8% ↘
FCF / Share $-0.09 →
Trailing P/E —
Price / Book 22.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 4, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.16K
↓ -82.8% —
Net Income Profit after all expenses
$-2.24M
↓ -41.6% —
Operating Margin Operating profit as % of sales
-53.8%
↑ +50.0% —
FCF / Share Free cash flow per share
$-0.09
↑ +1.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
1
Financial Health ↓
4
Cash Quality ↑
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 23 quarters